ASTERIAS BIOTHERAPEUTICS, INC. filed this 10-K on 20180315

Document Outline
Entire Document (5.8 MB)
Subdocument - 10-K - FORM 10-K
  Page 1 - UNITED STATES
  Page 2 - Asterias Biotherapeutics, Inc.
  Page 3 - PART I
  Page 4 - Corporate History
  Page 5 - Regenerative Medicine Advanced Therapy Designation and Orphan Drug Designation
  Page 6 - Manufacturing and Process Development
  Page 7 - AST-VAC2
  Page 8 - Services Agreement with Cell Therapy Catapult Services Limited
  Page 9 - Intellectual Property
  Page 10 - Neural cells
  Page 11 - License Agreement with University of California
  Page 12 - Royalty Agreement with Geron
  Page 13 - ex parte
  Page 14 - Government Regulation
  Page 15 - California State Regulations
  Page 16 - Risks Related to Our Business Operations
  Page 17 - We will spend a substantial amount of our capital on research and development, but we might not succ
  Page 18 - Adverse events in our clinical trials may force us to stop development of our product candidates or
  Page 19 - New products and technological advances by our competitors may negatively affect our results of oper
  Page 20 - We have no history of conducting large-scale, Phase 2 or 3 clinical trials or commercializing pharma
  Page 21 - Failure of our internal control over financial reporting could harm our business and financial resul
  Page 22 - Risks Related to Our Industry
  Page 23 - Government imposed bans or restrictions, and religious, moral and ethical concerns on the use of hES
  Page 24 - Legislative actions and potential new accounting pronouncements may impact our future financial
  Page 25 - Risks Related to Our Intellectual Property
  Page 26 - Intellectual property disputes with third parties and competitors may be costly and time consuming,
  Page 27 - Our reliance on third parties and agreements with collaboration partners requires us to share our tr
  Page 28 - Intellectual property rights do not address all potential threats to any competitive advantage we ma
  Page 29 - We have historically relied upon BioTime for certain services and resources.
  Page 30 - Risks Related to Our Dependence on Third Parties
  Page 31 - Industry and other market data used in our SEC filings, including market data undertaken by us or ou
  Page 32 - The price of our common stock, and the value of our assets, will be affected by changes in the value
  Page 33 - If securities analysts do not publish research or reports about our business or if they downgrade ou
  Page 34 - N/A
  Page 35 - PART II
  Page 36 - Asterias Biotherapeutics, Inc., the Amex Market Value and Amex Biotechnology Index
  Page 37 - N/A
  Page 38 - The following Management s Discussion and Analysis of Financial Condition and Results of Operations
  Page 39 - Available-for-sale securities, at fair value
  Page 40 - Research and development
  Page 41 - Fair value of financial instruments
  Page 42 - Operating Expenses
  Page 43 - Income Taxes
  Page 44 - Cash Flows
  Page 45 - N/A
  Page 46 - Contractual Obligations
  Page 47 - Report of Independent Registered Public Accounting Firm
  Page 48 - ASTERIAS BIOTHERAPEUTICS, INC.
  Page 49 - ASTERIAS BIOTHERAPEUTICS, INC.
  Page 50 - ASTERIAS BIOTHERAPEUTICS, INC.
  Page 51 - ASTERIAS BIOTHERAPEUTICS, INC.
  Page 52 - ASTERIAS BIOTHERAPEUTICS, INC.
  Page 53 - ASTERIAS BIOTHERAPEUTICS, INC.
  Page 54 - 2. Summary of Significant Accounting Policies
  Page 55 - Comprehensive income/loss
  Page 56 - Research and development
  Page 57 - Equity-Based Payments to Non-Employees
  Page 58 - Recently Adopted Accounting Pronouncements
  Page 59 - Leases (Topic 842),
  Page 60 - Compensation Stock Compensation: Scope of Modification
  Page 61 - 4. Investments in BioTime and OncoCyte Common Stock
  Page 62 - 6. Common Stock and Warrants
  Page 63 - Accounting for Derivative Financial Instruments Indexed to, and Potentially
  Page 64 - Warrants Outstanding in 2017, 2016 and 2015
  Page 65 - Stock Options
  Page 66 - Restricted Stock and Restricted Stock Units
  Page 67 - Staff Accounting Bulletin
  Page 68 - Fremont Lease
  Page 69 - Litigation General
  Page 70 - N/A
  Page 71 - 10. Income Taxes
  Page 72 - 11. Segment Information
  Page 73 - 13. License and Royalty Obligations
  Page 74 - Royalty Agreement with Geron
  Page 75 - Telomerase Sublicense from Geron
  Page 76 - 15. Cross-License and Share Transfer with BioTime and Subsidiaries
  Page 77 - Changes in Internal Control over Financial Reporting
  Page 78 - PART III
  Page 79 - PART IV
  Page 80 - ASTERIAS BIOTHERAPEUTICS, INC.
  Page 81 - N/A
  Page 82 - N/A
  Page 83 - N/A
  Page 84 - SIGNATURES
Subdocument - EX-23.1 - EXHIBIT 23.1
  Page 1 - Exhibit 23.1
Subdocument - EX-31.1 - EXHIBIT 31.1
  Page 1 - Exhibit 31.1
Subdocument - EX-31.2 - EXHIBIT 31.2
  Page 1 - Exhibit 31.2
Subdocument - EX-32.1 - EXHIBIT 32.1
  Page 1 - Exhibit 32.1